Vasco Pharmaceuticals

Vasco Pharma is a Belgian biotechnology company focused on developing therapies to combat vascular aging and associated rare genetic disorders. A spin-off from the University of Namur and the University of Liège, the company utilizes its proprietary Vasco-Aging platform to discover small molecule drugs that target cellular senescence within the vascular system. Its lead candidate, VP-001, is currently in pre-clinical development for Hutchinson-Gilford Progeria Syndrome (HGPS), a condition of premature aging. By addressing the root causes of vascular decline, Vasco Pharma aims to provide treatments for both orphan diseases and broader age-related cardiovascular pathologies. The company's approach combines deep expertise in molecular biology and vascular physiology to identify novel targets involved in the aging process.